Activity of estradiol and selective estrogen receptor modulators in the mouse N20.1 oligodendrocyte/astrocytes cell line

Neuroendocrinology Letters

Volumn 26, Issue 5, 2005, Pages 526-532

  Guzmán, Cristina B ^a   Deighton Collins, Sarah ^b   Martinez, Angela ^b   Kleerekoper, Michael ^a   Zhao, Changqing ^a   Benjamins, Joyce A ^a   Skafar, D F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Estrogen; Estrogen receptor; Glial cells; SERMs

Indexed keywords

4 HYDROXYTAMOXIFEN; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EXPRESSION VECTOR; MOUSE; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PROMOTER REGION; WESTERN BLOTTING;

EID: 29544447490     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Azcoitia I, Sierra A, Garcia-Segura LM. Localization of estrogen receptor-β immunoreactivity in astrocytes of the adult rat brain. Glia 1999; 26:260-267.
2. Beyer C. Estrogen and the developing mammalian brain. Anat Embryol 1999; 199:379-390.
3. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93:63-69.
4. Carroll RS, Zhang J, Black PM. Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 1999; 42(2):109-116.
5. Cui W, Allen ND, Skynner M, Gusterson B, Clark AJ. Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain. Glia 2001; 34:272-282.
6. Dhandapani KM, Brann DW. Estrogen-astrocyte interactions: implications for neuroprotection. BMC Neuroscience 2002, 3(1):6.
7. Dluzen DE, McDermott JL. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease. J Gen Specif Med 2000; 3:36-42.
8. Donahue JE, Stopa EG, Chorsky RL, King JC, Schipper HM, Tobet SA, Blaustein JD, Reichlin S. Cells containing immunoreactive estrogen receptor-alpha in the human basal forebrain. Brain Res 2000; 856:142-151.
9. Fisher B, Digman J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353(9169):1993-2000.
10. Garcia Ovejero D, Veiga S, Garcia-Segura LM, Doncarlos LL. Glial expression of estrogen and androgen receptors after rat brain injury. J Comp Neurol 2002; 26; 450(3):256-71.
11. Garcia -Segura LM, Azcoitia I, Don Carlos LL. Neuroprotection by estradiol. Prog Neurobiol 2001, 63:29-60.
12. Grainger DJ, Metcalfe JC. Tamoxifen: teaching an old drug new tricks. Nat Med 1996; 2:381-5.
13. Jakab RL, Wong JK, Belcher SM. Estrogen receptor beta immunoreactivity in differentiating cells of the developing rat cerebellum. J Comp Neurol 2001; 430:396-409.
14. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevenion trial. Lancet 1994; 343:1318-1321.
15. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uth RM, Webb P. Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry & Molecular Biology 2000; 74:311-317.
16. Laemmli UK. Cleavage of structural proteins during the assemly of the head of bacteriophage T4. Nature 1970; 227(259):680-5.
17. Langub MC Jr, Watson RE Jr. Estrogen receptor immunoreactive glia, endothelia, and ependyma in guinea pig preoptic area and median eminence: electron microscopy. Endocrinology 1992; 130:364-372.
18. Leranth C, Roth RH, Elsworth JD, Naftolin F, Horvatch TL, Edmond DE Jr. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 2000; 20:8604-8609.
19. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocrine Rev 1999; 20:279-307.
20. Milner TA, McEwen BS, Hayashi S, Li CJ, Reagan LP, Alves SE. Ultrastructural evidence that hippocampal alpha estrogen receptors are located at extranuclear sites. J Comp Neurol 2001, 429:355-371.
21. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 1998; 243(1):122-6.
22. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997; 277:1508-1510.
23. Pawlak J, Karolczak M, Krust A, Chambon P, Beyer C. Estrogen receptor-alpha is associated with the plasma.membrane of astrocytes and coupled to the MAP/Src-kinase pathway. Glia 2005 May; 50(3):270-5.
24. Philips A, Teyssier C, Galtier F, Rivier-Covas C, Rey JM, Rochefort H, Chalbos D. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol Endocrinol 1998; 12:973-98.
25. Platania P, Laureanti F, Bellomo M, Giuffrida R, Giuffrida-Stella AM, Catania MV, Sortino MA. Differential expression of estrogen receptors alpha and beta in the spinal cord during postnatal development: localization in glial cells. Neuroendocrinology 2003, 77:334-40.
26. Resnick SM, Maki PM. Effects of hormone replacement therapy on cognitive and brain aging. Ann NY Acad Sci 2001; 949:203-214.
27. Savaskan E, Olivieri G, Meier F, Ravid R, Muller-Spahn F. Hippocampal estrogen beta-receptor immunoreactivity is increased in Alzheimer's disease. Brain Res 2001; 908:113-119.
28. Schonknecht P, Pantel J, Klinga K, Jensen M, Hartmann T, Salbach B, Schroder J. Reduced cerebrospinal fluid estradiol levels are associated with increased beta-amyloid levels in female patients with Alzheimer's disease. Neurosci Lett 2001; 307;122-124.
29. Shumaker SA, Legault C, Rapp S, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J. Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women. JAMA 2003; 289(20):2651-2662.
30. Stone DJ, Song Y, Anderson CP, Khron KK, Finch CE, Rozovsky I. Bidirectional transcriptional regulation of glial fibrillary acidic protein by estradiol in vivo and in vitro. Endocrinology 1998; 139:3202-3209.
31. Studzinski DM, Callahan RE, Benjamins JA. Increased intracellular calcium alters myelin gene expression in the N20.1 oligodendroglial cell line. J Neurosci Res 1999; 75:633-42.
32. Swain SM: Tamoxifen: the long and short of it. J Natl Cancer Inst 1996; 88(21):1510-2.
33. Verity AN, Bredesen D, Vonderscher C, Handley VW, Campagnoni AT. Expression of myelin protein genes and other myelin components in an oligodendrocytic cell line conditionally immortalized with a temperature-sensitive retrovirus. J Neurochem 1993; 60:577-587.
34. Viviani B, Corsini E, Binaglia M, Lucchi L, Galli CL, Marinovich M. The anti-inflammatory activity of estrogen in glial cells is regulated by the PKC-anchoring protein RACK-1. Journal of Neurochemistry 2002; 83(5):1180-1187.
35. Wang L, Andersson S, Warner M, Gustafsson J. Morphological abnormalities in the brains of estrogen receptor β knockout mice. PNAS 2001, 98:2792-2796.
36. Webb P, Lopez GN, Uth RM, Kushner PJ. Tamoxifen activation of estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443-456.
37. Webb P, Nguyen P, Valentine C, Lopez G, et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999; 13:1672-1685.
38. Yaffe K et al. Estrogen therapy in postmenopausal women: effects in cognitive function and dementia. JAMA 1998; 279:688-695.
39. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJ, Glasebrook AL, Termine JD, Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 1996; 137:2075-2084.
40. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17b-estradiol and raloxifene. Science 1996, 273:1222-1225.
41. Zhang Z, Cerghet M, Mullins Ch, Williamson M, Bessert D, Skoff R. Comparison of in vivo and in vitro subcellular localization of estrogen receptors α and β in oligodendrocytes. J. Neurochem 2004; 89:674-684.